- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02907372
Impact of New Generation Hormono-therapy on Cognitive Functions in Elderly Patients Treated for a Metastatic Prostate Cancer (COG-PRO)
Study Overview
Status
Intervention / Treatment
Detailed Description
In this new area of multiples new treatments in advanced PCa that could be proposed to elderly patients, evaluating, understanding and analysing the incidence, severity of cognitive dysfunctions and their impact on quality of life, autonomy and adherence among this group of vulnerable patients with advanced disease is a challenge and is essential to help clinicians taking care of their patients. As the deficits may be subtle and not always related with complaints, cognitive functions need to be assessed by objective sensitive neuropsychological tests and by patient-perceived cognitive self-report questionnaire. In addition to the treatments,there is a range of potential confounders that can contribute to cognitive impairment, such as co-medications, psychological factors (e.g. anxiety or depression), fatigue, or cognitive reserve (i.e. patients with higher education, more occupational attainment, or participation in leisure activities report less clinical or cognitive changes with aging.
The evaluation and the comprehension of the cognitive decline in patients treated for a cancer are complex and need a multidisciplinary approach in human sciences in strong link to clinicians and biologist researchers.
Therefore, this study propose an original unique comprehensive interdisciplinary approach at the interface between public health, clinical research, psychology and biology which would have a direct impact on cancer patient care, including a consortium of neuropsychologists, oncologists and biologist researchers who are working together within the North West canceropole "cognition and cancer" program. In evaluating cognitive functions, mood, quality of life and adherence to treatments, fully in the scope of the proposal, will help to improve our knowledge in this new field of research in human health among cancer patients with a direct impact for the physicians and the patients. The strength of this project is to propose (in complement to the study conducted among patients) a comprehensive approach including an animal model with behavioural tasks as recommended by the ICCTF (International Cognition and Cancer Task Force).
This study will be the first one to address the question of the impact of the novel oral hormonal agents among elderly metastatic prostate cancer patients. This study will assess the influence of treatments on patients' cognitive functions on a longitudinal basis and evaluate the quality of life and the adherence of patients who had or develop cognitive disorders.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Amiens, France
- CHU
-
Caen, France
- Centre Francois Baclesse
-
Montpellier, France
- Institut régional du Cancer de Montpellier (ICM)
-
Rouen, France
- CHU Rouen
-
Suresnes, France
- Hopital Foch
-
Villejuif, France
- IGR
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
For the group of patients of interest :
- Patient must have a metastatic castration-resistant prostate cancer (CRPCa)
- Patient must be 70 years and more
- Performance Status 0-2
- Patient must have not received chemotherapy except one line per Docetaxel for hormono-sensitive situation and which must be completed for a least 18 months before inclusion
- Patient must have been already treated with first generation of androgen deprivation therapy
- Patient must be asymptomatic or pauci-symptomatic (with pain control, Visual Analog Scale ≤ 3)
- Patient must be candidate for a treatment by a new generation hormono-therapy (with abiraterone acetate or enzalutamide), in accordance to precautions of these treatments described in Summary Characteristics of Product and in combination with androgen deprivation therapy
- Treatment with biphosphonates is authorized
- No known brain metastasis
- Patient must be at least on level 3 on school scale
- Patient has signed informed consent
For the control group of patients :
- Patient with metastatic prostate cancer without resistance to castration
- Patient must be 70 years and more
- Performance Status 0-2
- Patient must have not received chemotherapy except one line per Docetaxel for hormono-sensitive situation and which must be completed for a least 18 months before inclusion
- Patient must have already started the first generation of androgen deprivation therapy at least since 3 months
- Patient must be asymptomatic or pauci-symptomatic (with pain control, Visual Analog Scale ≤ 3)
- No known brain metastasis
- Patient must be at least on level 3 on school scale
- Patient has signed informed consent
For the control group of healthy volunteers:
- Man
- No history of cancer,
- 70-year old or more,
- Health status consistent with the participation to the study
- At least on level 3 on school scale
- Signed informed consent
Exclusion Criteria:
For all participants (group of patients of interest, control group of patients and group of healthy volunteers):
- No previous treatment with a new generation hormone therapy (abiraterone acetate or enzalutamide)
- Neurological sequelae of (traumatic brain injury, stroke, multiple sclerosis, epilepsy, neuro-degenerative disease…)
- Known evolutive psychiatric disorder
- Drug use
- Heavy drinking
- Assessed to be unable or unwilling to comply with the requirements of the protocol
For group of patients of interest, additional non-inclusion criteria :
- Hypersensitivity to abiraterone acetate or enzalutamide
- For patients candidate for abiraterone acetate, presence of severe hepatic insufficiency
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Diagnostic
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Other: cognitive tests
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
The proportion of elderly patients who will experience a decline in cognitive performances (at least for one cognitive function) by questionnaires
Time Frame: 3 months after initiation of treatment by new generation hormono-therapies for a metastatic castration-resistant prostate cancer
|
3 months after initiation of treatment by new generation hormono-therapies for a metastatic castration-resistant prostate cancer
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
The quantitative score of cognitive functions by questionnaires
Time Frame: Within 12 months after initiation of treatment by new generation hormono-therapies for a metastatic castration-resistant prostate cancer
|
Within 12 months after initiation of treatment by new generation hormono-therapies for a metastatic castration-resistant prostate cancer
|
the quantitative score of quality of life by questionnaires for evaluate impact of cognitive impairment on quality of life to treatment
Time Frame: Within 12 months after initiation of treatment by new generation hormono-therapies for a metastatic castration-resistant prostate cancer
|
Within 12 months after initiation of treatment by new generation hormono-therapies for a metastatic castration-resistant prostate cancer
|
the quantitative score of anxiety/depression by questionnaires for evaluate impact of cognitive impairment
Time Frame: Within 12 months after initiation of treatment by new generation hormono-therapies for a metastatic castration-resistant prostate cancer
|
Within 12 months after initiation of treatment by new generation hormono-therapies for a metastatic castration-resistant prostate cancer
|
the quantitative score of fatigue by questionnaires for evaluate impact of cognitive impairment
Time Frame: Within 12 months after initiation of treatment by new generation hormono-therapies for a metastatic castration-resistant prostate cancer
|
Within 12 months after initiation of treatment by new generation hormono-therapies for a metastatic castration-resistant prostate cancer
|
the quantitative score of autonomy by geriatric evaluation for evaluate impact of cognitive impairment
Time Frame: Within 12 months after initiation of treatment by new generation hormono-therapies for a metastatic castration-resistant prostate cancer
|
Within 12 months after initiation of treatment by new generation hormono-therapies for a metastatic castration-resistant prostate cancer
|
the quantitative score of observance of treatment by questionnaire
Time Frame: Within 12 months after initiation of treatment by new generation hormono-therapies for a metastatic castration-resistant prostate cancer
|
Within 12 months after initiation of treatment by new generation hormono-therapies for a metastatic castration-resistant prostate cancer
|
Collaborators and Investigators
Sponsor
Collaborators
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2016-001248-20
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Metastatic Castration-resistant Prostate Cancer (CRPCa)
-
Myovant Sciences GmbHRecruitingMetastatic Castration-Resistant Prostate Cancer | Metastatic Castration-Sensitive Prostate Cancer | Non-Metastatic Castration-Resistant Prostate CancerUnited States
-
Janux TherapeuticsRecruitingProstate Cancer | Metastatic Castration-resistant Prostate Cancer | Castration Resistant Prostatic CancerUnited States, Australia
-
Universität des SaarlandesRecruitingProstate Cancer Metastatic | Advanced Prostate Carcinoma | Castration Resistant Prostatic CancerGermany
-
Sidney Kimmel Comprehensive Cancer Center at Johns...Clarus TherapeuticsRecruitingProstate Cancer | Castration-resistant Prostate Cancer | Metastatic Castration-resistant Prostate CancerUnited States
-
Vadim S KoshkinEli Lilly and Company; Prostate Cancer FoundationActive, not recruitingCastration-Resistant Prostate Carcinoma | Stage IV Prostate Cancer AJCC v8 | Stage IVA Prostate Cancer AJCC v8 | Stage IVB Prostate Cancer AJCC v8 | Metastatic Castration-resistant Prostate Cancer | Metastatic Prostate Adenocarcinoma | Metastatic Castration-resistant Prostate CarcinomaUnited States
-
Rohan GarjeJanssen Scientific Affairs, LLCNot yet recruitingCastration-resistant Prostate Cancer | Metastatic Prostate Cancer | Metastatic Castration-resistant Prostate CancerUnited States
-
BAMF HealthRecruitingMetastatic Castration-resistant Prostate CancerUnited States
-
Massachusetts General HospitalBayerCompletedProstate Cancer | Castration-resistant Prostate Cancer | Castration-resistant Prostate Cancer Metastatic to BoneUnited States
-
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.RecruitingMetastatic Castration-resistant Prostate CancerChina
-
Hinova Pharmaceuticals Inc.CompletedMetastatic Castration Resistant Prostate CancerChina
Clinical Trials on neuropsychologic evaluation
-
University Hospital, MontpellierCompletedProgressive Multiple Sclerosis | Multiple Sclerosis | Relapsing Remitting Multiple Sclerosis | ControlsFrance
-
University of PittsburghCompletedTrauma | Traumatic Brain Injury | Brain Concussion | Head InjuryUnited States
-
Assistance Publique Hopitaux De MarseilleUnknown
-
Yonsei UniversityCompletedElderly Patients Undergoing Spinal SurgeryKorea, Republic of
-
IRCCS Eugenio MedeaCompletedIntellectual Disability | Autism Spectrum Disorder | Attention Deficit Hyperactivity DisorderItaly
-
University Hospital, BordeauxRoche Pharma AGRecruitingMultiple Sclerosis, Primary ProgressiveFrance
-
University Hospital, BordeauxRecruitingMultiple SclerosisFrance
-
University of CatanzaroAzienda Sanitaria Provinciale Di Catanzaro; Azienda Ospedaliera Universitaria...Unknown
-
University Hospital, CaenRecruitingDementia | Alzheimer Disease | Mild Cognitive Impairment | Motoric Cognitive Risk SyndromeFrance
-
Ankara Yildirim Beyazıt UniversityCompletedType 2 Diabetes Mellitus | BalanceTurkey